Novartis Investigative Site
Villamartín, Cadiz 11650
0 studies enrolling now · 12 studies all time
What they study most
Acute Heart Failure, Acute Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure, Diabetes Mellitus and Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Heart Failure With Reduced Ejection Fraction (HF-rEF), Primary Prevention of Atherosclerotic Cardiovascular Disease
Studies at this site
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
- Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
- Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
- Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE
- Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
- A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure — Stopped early
- Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
- Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
- Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure — Completed
- Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed